BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Present Key Updates of Immuno-Oncology Tech at 2018 San Antonio Breast Cancer Symposium
BriaCell Therapeutics Corp. is working to develop the first off-the-shelf personalized immunotherapy for advanced breast cancer Clinical data reveals an excellent safety profile and potent anti-tumor activity for Bria-IMT in advanced breast cancer patients Combination study using Bria-IMT with Merck & Co., Inc.’s KEYTRUDA (pembrolizumab) in advanced breast cancer patients is ongoing Symposium covers the latest research on experimental biology, etiology, prevention, diagnosis and treatment of breast cancer and premalignant breast disease International audience from over 90 countries includes researchers, health professionals, physicians, oncologists and those with a special interest in breast cancer An immuno-oncology focused biotechnology company, BriaCell Therapeutics…